ClinicalTrials.gg
CompletedNCT04766723Updated Nov 13, 2026Results posted

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

A Phase 2 interventional study of NT 201 and Placebo in Essential Tremor of the Upper Limb, sponsored by Merz Pharmaceuticals GmbH. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Results publication addedPosted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.

Enrollment
27th of 104
78 · median 30
Started
2021
with 11 others
Phase 2
21 of 146
1 open now
Registered
103rd of 146
by date

Among the 146 studies in Essential Tremor with a site in United States, this one is the 27th largest by enrollment of the 104 interventional ones that give a count, is one of 12 that started in 2021, is one of 21 in phase 2, and was the 103rd registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Essential Tremor with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.

The following treatment cycle will investigate the safety and tolerability of two-sided treatment with NT 201 (botulinum toxin) (Open Label Bilateral Period). All participants will receive NT 201 treatment.

03

Conditions studied

  • Essential Tremor of the Upper Limb

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Score of ≥ 2 (at least 1 cm tremor amplitude) in at least two out of three maneuvers of test item 4 (upper limb tremor) of the TETRAS performances scale confirmed by an independent TETRAS expert by means of video assessment.

Exclusion criteria

Exclusion Criteria:

  • History or presence of day-to-day fluctuations in ET which would jeopardize meaningful tremor assessment over time, e.g. severe tremor on one day and minimal or no tremor on another day.
  • Other neurological signs, such as dystonia, ataxia, or parkinsonism, which in the judgment of the investigator could interfere with the ET diagnosis and/or assessment of ET in ULs.
  • Tremor types other than ET
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    NT 201 (IncobotulinumtoxinA, Xeomin)

    Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the motor-dominant upper limb. Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of both upper limbs.

    Drug: NT 201

  • Placebo comparator
    Placebo

    Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the motor-dominant upper limb. Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of both upper limbs.

    Drug: NT 201 · Drug: Placebo

Interventions

  • DrugNT 201

    Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

    Also known as: Incobotulinumtoxin A, IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins

  • DrugPlacebo

    Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

06

What researchers measure

Primary outcomes

  1. Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist

    TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement.

    Time frame: Baseline up to Week 6

Secondary outcomes

  1. Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator

    The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

    Time frame: Baseline up to Week 6

  2. Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score

    TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor \[items 2-9\]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

    Time frame: Baseline up to Week 6

  3. Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score

    TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

    Time frame: Baseline up to Week 6

  4. Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6

    The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

    Time frame: Week 6

  5. Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6

    The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

    Time frame: Week 6

  6. Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score

    TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

    Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)

  7. Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score

    The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity.

    Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)

  8. Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score

    TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

    Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)

  9. Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score

    TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

    Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)

  10. Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36).

    Time frame: Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)

07

Results

Posted Apr 28, 2026

Participant flow

Subjects were recruited at 14 investigational sites in the United States, Poland and Canada.

Unilateral Treatment: Cycle 1 (24 weeks)
Participant flow — Unilateral Treatment: Cycle 1 (24 weeks)
MilestoneUnilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboBilateral Treatment Period: NT 201
Started51270
Completed48260
Not completed310
Withdrew: Withdrawal by subject100
Withdrew: Adverse event100
Withdrew: Other110
Bilateral treatment: Cycle 2 (12 weeks)
Participant flow — Bilateral treatment: Cycle 2 (12 weeks)
MilestoneUnilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboBilateral Treatment Period: NT 201
Started0072
Completed0071
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryUnilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist

TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement.

Time frame:
Baseline up to Week 6
Reported as:
Least squares mean · degrees of arc
Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist
degrees of arcUnilateral Treatment Period: NT 201Unilateral Treatment Period: Placebo
Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist-0.25 ± 0.140-0.46 ± 0.180
Statistical analysis
  • Unilateral Treatment Period: NT 201 vs Unilateral Treatment Period: Placebo · Least square mean difference: 0.21 · 95% CI -0.18 to 0.61
SecondaryUnilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator

The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

Time frame:
Baseline up to Week 6
Reported as:
Mean · score on a scale
Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator
score on a scaleUnilateral Treatment Period: NT 201Unilateral Treatment Period: Placebo
Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator-2.3 ± 2.60-0.9 ± 1.56
SecondaryUnilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score

TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor \[items 2-9\]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

Time frame:
Baseline up to Week 6
Reported as:
Mean · score on a scale
Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score
score on a scaleUnilateral Treatment Period: NT 201Unilateral Treatment Period: Placebo
Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score-3.7 ± 5.00-3.8 ± 4.46
SecondaryUnilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score

TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

Time frame:
Baseline up to Week 6
Reported as:
Mean · score on a scale
Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score
score on a scaleUnilateral Treatment Period: NT 201Unilateral Treatment Period: Placebo
Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score-1.2 ± 1.87-1.3 ± 1.83
SecondaryUnilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6

The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

Time frame:
Week 6
Reported as:
Mean · score on a scale
Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6
score on a scaleUnilateral Treatment Period: NT 201Unilateral Treatment Period: Placebo
Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 60.9 ± 1.270.8 ± 1.14
SecondaryUnilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6

The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.

Time frame:
Week 6
Reported as:
Mean · score on a scale
Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6
score on a scaleUnilateral Treatment Period: NT 201Unilateral Treatment Period: Placebo
Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 61.2 ± 1.360.8 ± 1.03
SecondaryBilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score

TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.

Time frame:
Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Reported as:
Mean · score on a scale
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score
score on a scaleBilateral Treatment Period: NT 201
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score-2.8 ± 2.62
SecondaryBilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score

The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity.

Time frame:
Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)
Reported as:
Mean · score on a scale
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score
score on a scaleBilateral Treatment Period: NT 201
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score-5.6 ± 5.14
SecondaryBilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score

TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.

Time frame:
Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Reported as:
Mean · score on a scale
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score
score on a scaleBilateral Treatment Period: NT 201
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score-4.4 ± 4.07
SecondaryBilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score

TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.

Time frame:
Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Reported as:
Mean · score on a scale
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score
score on a scaleBilateral Treatment Period: NT 201
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score-1.4 ± 1.42
SecondaryPercentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36).

Time frame:
Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)
Reported as:
Number · percentage of subjects
Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)
percentage of subjectsUnilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboBilateral Treatment Period: NT 201
Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)30.03.730.6

Adverse events

Collected over Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study (Week 36). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Unilateral Treatment Period: NT 2010/50 (0%)3/50 (6%)29/50 (58%)
Unilateral Treatment Period: Placebo0/27 (0%)2/27 (7.4%)5/27 (18.5%)
Bilateral Treatment Period: NT 2010/72 (0%)2/72 (2.8%)29/72 (40.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventUnilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboBilateral Treatment Period: NT 201
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/501/270/72
AspirationRespiratory, thoracic and mediastinal disorders0/501/270/72
DyspnoeaRespiratory, thoracic and mediastinal disorders0/501/270/72
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/500/270/72
Condition aggravatedGeneral disorders1/500/270/72
CholelithiasisHepatobiliary disorders1/500/270/72
PneumoniaInfections and infestations1/500/270/72
Skull fractureInjury, poisoning and procedural complications0/500/271/72
Subdural haematomaInjury, poisoning and procedural complications0/500/271/72
Atrial fibrillationCardiac disorders0/500/271/72
Most frequent other events
Showing 10 of 72
Most frequent other events
EventUnilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboBilateral Treatment Period: NT 201
Muscular weaknessMusculoskeletal and connective tissue disorders12/500/2717/72
FallInjury, poisoning and procedural complications1/502/273/72
HypertensionVascular disorders3/500/270/72
Back painMusculoskeletal and connective tissue disorders3/500/270/72
Injection site haemorrhageGeneral disorders2/501/270/72
Pain in extremityMusculoskeletal and connective tissue disorders2/500/271/72
Herpes zosterInfections and infestations2/500/270/72
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/501/270/72
FatigueGeneral disorders0/501/270/72
Influenza like illnessGeneral disorders0/501/270/72

Baseline characteristics

Randomized population.

Age, Customized
Age, Customized(Participants)Unilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboTotal
18-64 years181129
65-84 years321547
>= 85 years112
Sex: Female, Male
Sex: Female, Male(Participants)Unilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboTotal
Female251237
Male261541
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Unilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino502676
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Unilateral Treatment Period: NT 201Unilateral Treatment Period: PlaceboTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White492675
More than one race000
Unknown or Not Reported101
08

Study locations

14 sites
  • USF, Department of Neurology, Merz Investigational Site #0010020
    Tampa, Florida 33612, United States
  • University of Nebraska Medical Center, Merz Investigational Site #0010269
    Omaha, Nebraska 68131, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health, Merz Investigational Site #0010457
    Las Vegas, Nevada 89106, United States
  • Mount Sinai Medical Center, Merz Investigational Site #0010191
    New York, New York 10029, United States
  • Vanderbilt University Medical Center, Neuroscience Institute, Merz Investigational Site #0010206
    Nashville, Tennessee 37232, United States
  • Houston Methodist Neurological Institute, Merz Investigational Site #0010226
    Houston, Texas 77030, United States
  • Medstar Georgetown Neurology, Merz Investigational Site #0010231
    McLean, Virginia 22101, United States
  • UW Medical Center - Montlake, Merz Investigational Site #0010450
    Seattle, Washington 98195, United States
  • Selkirk Neurology, Merz Investigational Site #0010456
    Spokane, Washington 99202, United States
  • London Health Sciences Centre, Merz Investigational Site #0010087
    London, Ontario N6A 5A5, Canada
  • Specjalistyczne Gabinety, Merz Investigational Site #0480059
    Krakow, 30-539, Poland
  • NeuroKlinika Gabinet Lekarski, Merz Investigational Site #0480101
    Lodz, 90-640, Poland
  • Instytut Zdrowia Dr. Boczarska-Jedynak
    Oświęcim, 32-600, Poland
  • Mazowiecki Szpital Bródnowski, Merz Investigational Site #0480064
    Warsaw, 03-242, Poland
09

References and documents

Publications

  • Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, Bagretsova A, Klein G, Geister TL, Pulte I, Jog M. IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial. Toxins (Basel). 2026 Oct 9;18(10):435. doi: 10.3390/toxins18100435. PubMed 42931526 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2023, 26 months.

Results were first posted in Apr 2026, 3 years after primary completion. A results delay was requested in Apr 2024.

Of 20 phase 2 interventional studies under Essential Tremor, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2021
First posted
Feb 23, 2021
StartActual
Feb 24, 2021
Primary completionActual
Apr 26, 2023
CompletionActual
Nov 21, 2023
Results delay requested
Apr 19, 2024
Results first posted
Apr 28, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 13, 2026
Publications
Results publication added: Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, Bagretsova A, Klein G, Geister TL, Pulte I, Jog M. IncobotulinumtoxinA for Upper Limb Essential Tremor:… PubMed 42931526 ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Posted results revised
    Publications Results publication added: Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, Bagretsova A, Klein G, Geister TL, Pulte I, Jog M. IncobotulinumtoxinA for Upper Limb Essential Tremor:… PubMed 42931526 ↗

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04766723
Responsible party
Sponsor
First posted
Feb 23, 2021
Start date
Feb 24, 2021
Primary completion
Apr 26, 2023
Completion
Nov 21, 2023
Results posted
Apr 28, 2026
Last update
Nov 13, 2026

Study contacts

Merz Medical Expert
study director · Merz Pharmaceuticals GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: incobotulinumtoxinA

Start the discussion